Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | PAM | P19021 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL530570 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL2352340 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL8518463 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL5384786 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL4953759 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL8601641 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL1921958 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL1925892 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL433597 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 | |
| Acetic Acid SCHEMBL717375 | 1.00 | MEN1 (0.58) | MEN1KMT2AMAPTATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334684-B1 | PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| EP-2300478-B1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-9102679-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9096603-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9079905-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-8946243-B2 | Compounds and methods for the treatment of viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140350025-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| CN-101983199-B | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators | BOEHRINGER INGELHEIM INT | 2014-11-05 | — | — | CN | disclosed |
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20140073641-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-5506262-A | ANTICHOLESTEROL AGENTS, FUNGICIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-04-09 | — | — | US | disclosed |
| US-5476863-A | Inhibitors of platelet activating factor and diseases caused thereby; stability | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5476864-A | Therapy for diseases caused by platelet activation factor | EISAI CO., LTD. (JP) | 1995-12-19 | — | — | US | disclosed |
| EP-0353474-B1 | Glycerin derivative and its pharmacological use | EISAI CO LTD (JP) | 1995-04-05 | — | — | EP | disclosed |
| US-5273985-A | A 1-phenylaminocarbonyl-2-sulfoamidophenyleneamino-3-pyrid-2-ylaminocarbonyl glyceride | EISAI CO., LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| WO-1992020336-A2 | NOVEL CHOLESTEROL LOWERING COMPOUNDS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0512865-A2 | Novel cholesterol lowering compounds | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| US-5037827-A | Useful for treatment of disease caused by platelet activating factory | EISAI CO., LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0353474-A2 | Glycerin derivative and its pharmacological use | Eisai Co., Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| CN-1039414-A | Glycerol derivatives and pharmaceutical use thereof | EISAI CO LTD (JP) | 1990-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350025-A1 | COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | CHRM1, ATP6V1B2, CNR1 | ESR1 3185/4885MEN1 1193/4885KMT2A 1385/4885 |
| US-20140073641-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | PDE9A, PDE7A, PDE1A | ESR1 2651/4885MEN1 2514/4885KMT2A 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.